ALGS...$7.30...🥳...Off my $6.60 alert...Psar flipped Bullish...
georgie18
Member Level
Re: tw0122 post# 44
Sunday, November 16, 2025 8:34:41 AM
Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.
georgie18
Member Level
Re: tw0122 post# 44
Sunday, November 16, 2025 8:34:41 AM
Post#
47
of 47
ALGS...$6.66...🥳... Bullish Engulfing Reversal Pattern... https://schrts.co/rSUukrzs ... The company has $99.10 million in cash and $6.07 million in debt, giving a net cash position of $93.03 million or $15.12 per share.
Recent ALGS News
- Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 • GlobeNewswire Inc. • 05/13/2026 06:05:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:08:02 PM
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/07/2026 08:05:00 PM
- Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 08:33:53 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 08:29:42 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:25:49 PM
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/24/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:32:46 PM
- Aligos Therapeutics Jumps on China Licensing Agreement • IH Market News • 04/16/2026 02:22:44 PM
- Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection • GlobeNewswire Inc. • 04/16/2026 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2026 08:17:32 PM
- Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation • GlobeNewswire Inc. • 04/14/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 08:14:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/05/2026 01:28:14 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 01:08:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:01:42 PM
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 10:54:15 PM
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/30/2026 01:00:00 PM
- Aligos Therapeutics edges higher after update on Phase 2 HBV trial • IH Market News • 01/21/2026 03:47:22 PM
- Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates • GlobeNewswire Inc. • 01/21/2026 01:00:00 PM
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer • GlobeNewswire Inc. • 01/13/2026 01:00:00 PM
